249 related articles for article (PubMed ID: 24560135)
21. Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia.
Melenovsky V; Wichterle D; Simek J; Malik J; Haas T; Ceska R; Malik M
Am J Cardiol; 2003 Aug; 92(3):337-41. PubMed ID: 12888150
[TBL] [Abstract][Full Text] [Related]
22. Effect of atorvastatin on pancreatic Beta-cell function and insulin resistance in type 2 diabetes mellitus patients: a randomized pilot study.
Goyal A; Singh S; Tandon N; Gupta N; Gupta YK
Can J Diabetes; 2014 Dec; 38(6):466-72. PubMed ID: 24933106
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus.
Su Y; Xu Y; Sun YM; Li J; Liu XM; Li YB; Liu GD; Bi S
J Cardiovasc Pharmacol; 2010 Jan; 55(1):21-5. PubMed ID: 19786892
[TBL] [Abstract][Full Text] [Related]
24. Acute effects of atorvastatin on glomerular filtration rate, tubular function, blood pressure, and vasoactive hormones in patients with type 2 diabetes.
Paulsen L; Matthesen SK; Bech JN; Starklint J; Pedersen EB
J Clin Pharmacol; 2010 Jul; 50(7):816-22. PubMed ID: 20056802
[TBL] [Abstract][Full Text] [Related]
25. [A dyslipidemia animal model induced by poloxamer 407 in golden hamsters and pilot study on the mechanism].
Liu Q; Liu SN; Li LY; Chen ZY; Lei L; Zhang N; Shen ZF
Yao Xue Xue Bao; 2011 Apr; 46(4):406-11. PubMed ID: 21751494
[TBL] [Abstract][Full Text] [Related]
26. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
Winkler K; Weltzien P; Friedrich I; Schmitz H; Nickell HH; Hauck P; Hoffmann MM; Baumstark MW; Wieland H; März W
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):241-7. PubMed ID: 15146369
[TBL] [Abstract][Full Text] [Related]
27. Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes.
Anderlová K; Dolezalová R; Housová J; Bosanská L; Haluzíková D; Kremen J; Skrha J; Haluzík M
Physiol Res; 2007; 56(5):579-586. PubMed ID: 17184146
[TBL] [Abstract][Full Text] [Related]
28. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.
Belfort R; Berria R; Cornell J; Cusi K
J Clin Endocrinol Metab; 2010 Feb; 95(2):829-36. PubMed ID: 20061429
[TBL] [Abstract][Full Text] [Related]
29. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
Davidson MH; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Mazzone T; Carlson DM; Williams LA; Kelly MT; Camp HS; Lele A; Stolzenbach JC
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1298-306. PubMed ID: 24743431
[TBL] [Abstract][Full Text] [Related]
30. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
[TBL] [Abstract][Full Text] [Related]
31. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
[TBL] [Abstract][Full Text] [Related]
32. Atorvastatin prevents type 2 diabetes mellitus--an experimental study.
Madhu SV; Aslam M; Galav V; Bhattacharya SK; Jafri AA
Eur J Pharmacol; 2014 Apr; 728():135-40. PubMed ID: 24530420
[TBL] [Abstract][Full Text] [Related]
33. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects.
Tannous M; Cheung R; Vignini A; Mutus B
Thromb Haemost; 1999 Nov; 82(5):1390-4. PubMed ID: 10595624
[TBL] [Abstract][Full Text] [Related]
34. Opposite effects of pravastatin and atorvastatin on insulin sensitivity in the rat: role of vitamin D metabolites.
Bełtowski J; Atanassova P; Chaldakov GN; Jamroz-Wiśniewska A; Kula W; Rusek M
Atherosclerosis; 2011 Dec; 219(2):526-31. PubMed ID: 21889144
[TBL] [Abstract][Full Text] [Related]
35. Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes.
Ong KL; Rye KA; O'Connell R; Jenkins AJ; Brown C; Xu A; Sullivan DR; Barter PJ; Keech AC;
J Clin Endocrinol Metab; 2012 Dec; 97(12):4701-8. PubMed ID: 23144467
[TBL] [Abstract][Full Text] [Related]
36. Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice.
Suzuki M; Kakuta H; Takahashi A; Shimano H; Tada-Iida K; Yokoo T; Kihara R; Yamada N
J Atheroscler Thromb; 2005; 12(2):77-84. PubMed ID: 15942117
[TBL] [Abstract][Full Text] [Related]
37. Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes.
Mose FH; Larsen T; Jensen JM; Hansen AB; Bech JN; Pedersen EB
Scand J Clin Lab Invest; 2014 Jan; 74(1):8-19. PubMed ID: 24256611
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
Terra SG; Francone OL; Contant CF; Gao X; Lewin AJ; Nguyen TT
Am J Cardiol; 2008 Aug; 102(4):434-9. PubMed ID: 18678301
[TBL] [Abstract][Full Text] [Related]
39. Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.
Stirban AO; Andjelkovic M; Heise T; Nosek L; Fischer A; Gastaldelli A; Herz M
Diabetes Obes Metab; 2016 Jul; 18(7):711-5. PubMed ID: 26663152
[TBL] [Abstract][Full Text] [Related]
40. The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes.
Braatvedt GD; Bagg W; Gamble G; Davidson J; Reid IR
Bone; 2004 Sep; 35(3):766-70. PubMed ID: 15336614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
